155 related articles for article (PubMed ID: 17191217)
21. N-hydroxyurea and hydroxamic acid inhibitors of cyclooxygenase and 5-lipoxygenase.
Connolly PJ; Wetter SK; Beers KN; Hamel SC; Chen RH; Wachter MP; Ansell J; Singer MM; Steber M; Ritchie DM; Argentieri DC
Bioorg Med Chem Lett; 1999 Apr; 9(7):979-84. PubMed ID: 10230624
[TBL] [Abstract][Full Text] [Related]
22. 2-Arylbenzo[b]furan derivatives as potent human lipoxygenase inhibitors.
Lang L; Dong N; Wu D; Yao X; Lu W; Zhang C; Ouyang P; Zhu J; Tang Y; Wang W; Li J; Huang J
J Enzyme Inhib Med Chem; 2016; 31(sup4):98-105. PubMed ID: 27590167
[TBL] [Abstract][Full Text] [Related]
23. QSAR of matrix metalloproteinase inhibitor N-[(substituted phenyl)sulfonyl]-N-4-nitrobenzylglycine hydroxamates using LFER model.
Roy K; Pal DK; De AU; Sengupta C
Drug Des Discov; 2001; 17(4):315-23. PubMed ID: 11765134
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of electronic, lipophilic and membrane affinity effects on antiproliferative activity of 5-substituted-2-(2,4-dihydroxyphenyl)-1,3,4-thiadiazoles against various human cancer cells.
Matysiak J
Eur J Med Chem; 2007 Jul; 42(7):940-7. PubMed ID: 17320247
[TBL] [Abstract][Full Text] [Related]
25. Design and synthesis of eugenol derivatives, as potent 15-lipoxygenase inhibitors.
Sadeghian H; Seyedi SM; Saberi MR; Arghiani Z; Riazi M
Bioorg Med Chem; 2008 Jan; 16(2):890-901. PubMed ID: 17998164
[TBL] [Abstract][Full Text] [Related]
26. 6-substituted purines as inhibitors of 15-lipoxygenase; a structure-activity study.
Bråthe A; Gundersen LL; Malterud KE; Rise F
Arch Pharm (Weinheim); 2005 Apr; 338(4):159-66. PubMed ID: 15864785
[TBL] [Abstract][Full Text] [Related]
27. Potent inhibitors of 5-lipoxygenase identified using pseudoreceptors.
Rödl CB; Tanrikulu Y; Wisniewska JM; Proschak E; Schneider G; Steinhilber D; Hofmann B
ChemMedChem; 2011 Jun; 6(6):1001-5. PubMed ID: 21506275
[No Abstract] [Full Text] [Related]
28. Naphthalenic lignan lactones as selective, nonredox 5-lipoxygenase inhibitors. Synthesis and biological activity of (methoxyalkyl)thiazole and methoxytetrahydropyran hybrids.
Ducharme Y; Brideau C; Dubé D; Chan CC; Falgueyret JP; Gillard JW; Guay J; Hutchinson JH; McFarlane CS; Riendeau D
J Med Chem; 1994 Feb; 37(4):512-8. PubMed ID: 8120869
[TBL] [Abstract][Full Text] [Related]
29. QSAR study on 5-lipoxygenase inhibitors using distance-based topological indices.
Agrawal VK; Bano S; Khadikar PV
Bioorg Med Chem; 2003 Dec; 11(24):5519-27. PubMed ID: 14642596
[TBL] [Abstract][Full Text] [Related]
30. Symmetrical bis-quinolinium compounds: new human choline kinase inhibitors with antiproliferative activity against the HT-29 cell line.
Sánchez-Martín R; Campos JM; Conejo-García A; Cruz-López O; Báñez-Coronel M; Rodríguez-González A; Gallo MA; Lacal JC; Espinosa A
J Med Chem; 2005 May; 48(9):3354-63. PubMed ID: 15857141
[TBL] [Abstract][Full Text] [Related]
31. Comparative QSAR modeling of COX-2 inhibitor 1,2-diarylimidazoles using E-state and physicochemical parameters.
Chakraborty S; Sengupta C; Roy K
Indian J Biochem Biophys; 2007 Jun; 44(3):169-75. PubMed ID: 17650586
[TBL] [Abstract][Full Text] [Related]
32. Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Prado-Prado FJ; Martinez de la Vega O; Uriarte E; Ubeira FM; Chou KC; González-Díaz H
Bioorg Med Chem; 2009 Jan; 17(2):569-75. PubMed ID: 19112024
[TBL] [Abstract][Full Text] [Related]
33. QSAR study on dual 5-HT1A and 5-HT1B antagonists: an insight into the structural requirement for antidepressant activity.
Dessalew N
Arch Pharm (Weinheim); 2008 May; 341(5):314-22. PubMed ID: 18389517
[TBL] [Abstract][Full Text] [Related]
34. Novel and potent inhibitors of 5-lipoxygenase product synthesis based on the structure of pirinixic acid.
Werz O; Greiner C; Koeberle A; Hoernig C; George S; Popescu L; Syha I; Schubert-Zsilavecz M; Steinhilber D
J Med Chem; 2008 Sep; 51(17):5449-53. PubMed ID: 18710209
[TBL] [Abstract][Full Text] [Related]
35. QSAR study on 5-lipoxygenase inhibitors based on support vector machine.
Niu B; Su Q; Yuan X; Lu W; Ding J
Med Chem; 2012 Nov; 8(6):1108-16. PubMed ID: 22779798
[TBL] [Abstract][Full Text] [Related]
36. Molecular modeling of histamine H3 receptor and QSAR studies on arylbenzofuran derived H3 antagonists.
Dastmalchi S; Hamzeh-Mivehroud M; Ghafourian T; Hamzeiy H
J Mol Graph Model; 2008 Jan; 26(5):834-44. PubMed ID: 17561422
[TBL] [Abstract][Full Text] [Related]
37. A quantitative structure-activity relationship study on some series of anthranilic acid-based matrix metalloproteinase inhibitors.
Gupta SP; Kumaran S
Bioorg Med Chem; 2005 Sep; 13(18):5454-62. PubMed ID: 15993609
[TBL] [Abstract][Full Text] [Related]
38. QSAR study of imidazoline antihypertensive drugs.
Nikolic K; Filipic S; Agbaba D
Bioorg Med Chem; 2008 Aug; 16(15):7134-40. PubMed ID: 18621536
[TBL] [Abstract][Full Text] [Related]
39. Class II-selective histone deacetylase inhibitors. Part 2: alignment-independent GRIND 3-D QSAR, homology and docking studies.
Ragno R; Simeoni S; Rotili D; Caroli A; Botta G; Brosch G; Massa S; Mai A
Eur J Med Chem; 2008 Mar; 43(3):621-32. PubMed ID: 17698257
[TBL] [Abstract][Full Text] [Related]
40. Cytokines in terms of QSAR. Review, evaluation and comparative studies.
Konstantinidou M; Hadjipavlou-Litina D
SAR QSAR Environ Res; 2013 Nov; 24(11):883-962. PubMed ID: 24099567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
